Xencor, Inc.
XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndromeā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.55
Price-0.89%
-$0.14
1Y
Price
Market Cap
$1.110b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+20.1%
EBITDA Margin-28.7%
Net Profit Margin-147.6%
Free Cash Flow MarginRevenue
$167.357m
+51.5%
1y CAGR+7.0%
3y CAGR-4.8%
5y CAGREarnings
-$138.749m
+40.4%
1y CAGR-58.5%
3y CAGR-85.6%
5y CAGREPS
-$1.88
+47.5%
1y CAGR-49.4%
3y CAGR-79.0%
5y CAGRBook Value
$625.316m
$868.811m
Assets$243.495m
Liabilities$202.405m
DebtDebt to Assets
23.3%
-2.9x
Debt to EBITDAFree Cash Flow
-$143.674m
+31.0%
1y CAGR-164.8%
3y CAGR-113.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company